• 4 results in Exploration of Digestive Diseases
    Sort by
    Latest
    Open Access
    Review
    Deciphering the liver enigma: distinguishing drug-induced liver injury and metabolic dysfunction-associated steatotic liver disease—a comprehensive narrative review
    Drug-induced liver injury (DILI) poses a complex and heterogeneous clinical challenge, which often resembles non-drug related acute or chronic liver diseases, such as metabolic dysfunction-associate [...] Read more.
    Miren García-Cortés ... Alberto García-García
    Published: December 27, 2023 Explor Dig Dis 2023;2:318–336
    DOI: https://doi.org/10.37349/edd.2023.00034
    This article belongs to the special issue Drug-induced Liver Injury: From Bench to Clinical Application
    View:781
    Download:23
    Times Cited: 0
    Open Access
    Original Article
    The significance of chronic hyperglycemia for the reduced efficacy of eradication therapy in patients with type 2 diabetes mellitus and for Helicobacter pylori survival
    Aim: This study aims to determine the significance of chronic hyperglycemia for the reduced efficacy of eradication therapy in patients with type 2 diabetes mellitus (T2DM) and Helicobacter pylor [...] Read more.
    Luiza Gilmanovna Bektemirova ... Vasiliy Ivanovich Reshetnyak
    View:467
    Download:11
    Times Cited: 0
    Open Access
    Original Article
    Impact of the direct acting antivirals on chronic hepatitis C prevalence on the Swiss organ transplantation list: a retrospective analysis
    Aim: In Switzerland, the first access to interferon-free direct-acting antivirals (DAAs) for hepatitis C virus (HCV) treatment was in 2014. This study aimed to analyze the effects of DAAs on the  [...] Read more.
    Luis Falcato ... Franz Immer
    Published: December 25, 2023 Explor Dig Dis. 2023;2:297–304
    DOI: https://doi.org/10.37349/edd.2023.00032
    This article belongs to the special issue Chronic Hepatitis B and C
    View:451
    Download:18
    Times Cited: 0
    Open Access
    Review
    Therapeutic targets for metabolic dysfunction-associated steatotic liver disease and their roles in hepatocellular carcinoma
    Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most common chronic liver diseases. Over time, there has been a significant increase in the prevalence of MASLD. It has [...] Read more.
    Chenyu Wei ... Xianguang Yang
    Published: December 13, 2023 Explor Dig Dis. 2023;2:282–296
    DOI: https://doi.org/10.37349/edd.2023.00031
    This article belongs to the special issue Cellular and Molecular Targets for NAFLD or MAFLD Treatments and Their Functions in Liver Fibrosis, Cirrhosis, and Cancer
    View:794
    Download:21
    Times Cited: 0